Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be competitive with other Crohn’s, colitis medicines in testing.
Revenues in the biopharma industry continued to boom in the fourth quarter of last year, following a pattern seen ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...
Teva and Sanofi's duvakitug showed promising results in a Phase 2b study for ulcerative colitis and Crohn's disease, with ...
Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...
Eli Lilly said on Tuesday it has begun selling higher doses of its popular weight-loss drug Zepbound in vials in the U.S. at ...
Drug compounders on Monday sued the U.S. Food and Drug Administration over its decision last week to remove Novo Nordisk's ...
HRG reviewed five products in the health category, 47 items in the wellness sector and 140 products in the beauty aisle to ...
The Top 100 Healthcare Technology Companies list is curated by a renowned industry research organization that evaluates ...
The top rate on one of those accounts is only slightly ... See details on our list of best bank bonuses. Online Savings Account details from Discover: "Annual Percentage Yield (APY) is accurate ...
Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 3298.64 Cr. and Equity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback